These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 39181188

  • 21. MicroRNAs Correlate with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in a Chinese Population.
    Chen J, Zhu J, Wang Z, Yao X, Wu X, Liu F, Zheng W, Li Z, Lin A.
    Med Sci Monit; 2017 May 27; 23():2565-2583. PubMed ID: 28550707
    [Abstract] [Full Text] [Related]

  • 22. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
    Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Clerici M.
    J Transl Med; 2015 May 07; 13():148. PubMed ID: 25947625
    [Abstract] [Full Text] [Related]

  • 23. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
    Shimizu F, Tasaki A, Sano Y, Ju M, Nishihara H, Oishi M, Koga M, Kawai M, Kanda T.
    PLoS One; 2014 May 07; 9(3):e92872. PubMed ID: 24686948
    [Abstract] [Full Text] [Related]

  • 24. Multiple sclerosis by phenotype in Germany.
    Engelhard J, Oleske DM, Schmitting S, Wells KE, Talapala S, Barbato LM.
    Mult Scler Relat Disord; 2022 Jan 07; 57():103326. PubMed ID: 35158442
    [Abstract] [Full Text] [Related]

  • 25. MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.
    Zanghì A, Manuti V, Serviddio G, D'Amico E, Avolio C.
    Front Immunol; 2023 Jan 07; 14():1226130. PubMed ID: 37711630
    [Abstract] [Full Text] [Related]

  • 26. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
    Kopp TI, Bramow S, Illes Z, Kant M, Kristensen C, Rasmussen PV, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2021 Nov 07; 56():103319. PubMed ID: 34666241
    [Abstract] [Full Text] [Related]

  • 27. Assessment of serum inflammatory parameters in RRMS and SPMS patients.
    Nowak-Kiczmer M, Niedziela N, Czuba ZP, Sowa P, Wierzbicki K, Lubczyński M, Adamczyk-Sowa M.
    Neurol Res; 2024 Jun 07; 46(6):495-504. PubMed ID: 38697017
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L, Lucchesi C, Pecori C, Metelli MR, Pellegrini S, Iudice A, Bonuccelli U.
    J Neuroimmunol; 2015 Jan 15; 278():53-9. PubMed ID: 25595252
    [Abstract] [Full Text] [Related]

  • 31. The Faces of "Too Late"-A Surprisingly Progressive Cohort of "Stable" Relapsing Remitting Multiple Sclerosis Patients.
    Ciubotaru A, Grosu C, Alexa D, Covali R, Maștaleru A, Leon MM, Schreiner TG, Ghiciuc CM, Roman EM, Azoicăi D, Ignat EB.
    Medicina (Kaunas); 2024 Aug 26; 60(9):. PubMed ID: 39336442
    [Abstract] [Full Text] [Related]

  • 32. Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients.
    Ghadiri N, Emamnia N, Ganjalikhani-Hakemi M, Ghaedi K, Etemadifar M, Salehi M, Shirzad H, Nasr-Esfahani MH.
    Gene; 2018 Jun 15; 659():109-117. PubMed ID: 29551498
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells.
    Sanders KA, Benton MC, Lea RA, Maltby VE, Agland S, Griffin N, Scott RJ, Tajouri L, Lechner-Scott J.
    Clin Epigenetics; 2016 Jun 15; 8(1):87. PubMed ID: 27570566
    [Abstract] [Full Text] [Related]

  • 35. Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.
    Nali LH, Olival GS, Sousa FTG, de Oliveira ACS, Montenegro H, da Silva IT, Dias-Neto E, Naya H, Spangenberg L, Penalva-de-Oliveira AC, Romano CM.
    Mult Scler Relat Disord; 2020 Sep 15; 44():102243. PubMed ID: 32559700
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders.
    Perdaens O, Dang HA, D'Auria L, van Pesch V.
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar 05; 7(2):. PubMed ID: 32033981
    [Abstract] [Full Text] [Related]

  • 38. Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis.
    El Ayoubi NK, Sabbagh HM, Bou Rjeily N, Hannoun S, Khoury SJ.
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov 05; 9(6):. PubMed ID: 36229190
    [Abstract] [Full Text] [Related]

  • 39. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R, Søndergaard HB, Christensen JR, Börnsen L, Borup R, Sørensen PS, Sellebjerg F.
    Mult Scler; 2013 Dec 05; 19(14):1841-8. PubMed ID: 24085340
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.